Andrew Barnell, WG’17

Geneoscopy LLC, a life sciences Company Andrew started during his time at Wharton, raised $1.0 million to advance its stool-derived eukaryotic RNA (seRNA) diagnostic testing platform. Geneoscopy’s method to extract and analyze seRNA enables accurate and non-invasive diagnostic tests to prevent, detect, and monitor gastrointestinal (GI) disease. Funds will be used to advance the company’s lead product, a preventive screening test to diagnose colorectal cancer and precancerous adenomas in asymptomatic individuals, as well as several other pipeline products.

Contact Andrrew at:
[email protected]


Learn more.


Back to the Alumni News list.